Xiufan Liu Selected Research

Influenza in Birds (Avian Flu)

12/2022	Generation of an avian influenza DIVA vaccine with a H3-peptide replacement located at HA2 against both highly and low pathogenic H7N9 virus.
8/2022	Characterization of antibody response to an epitope spanning the haemagglutinin cleavage site of H7N9 subtype avian influenza virus for the differentiation of infected and vaccinated chickens.
6/2022	HA gene amino acid mutations contribute to antigenic variation and immune escape of H9N2 influenza virus.
5/2022	Characterization of two chicken origin highly pathogenic H7N9 viruses isolated in northern China.
3/2022	Effects of HA2 154 deglycosylation and NA V202I mutation on biological property of H5N6 subtype avian influenza virus.
1/2022	[Characterization of a monoclonal antibody against the hemagglutinin stem of H7N9 subtype avian influenza virus].
1/2022	Emerging of H5N6 Subtype Influenza Virus with 129-Glycosylation Site on Hemagglutinin in Poultry in China Acquires Immune Pressure Adaption.
1/2022	Expression and characterization of a recombinant broadly-reactive monoclonal antibody against group 1 and 2 influenza viruses.
1/2022	Intranasal Immunization with a Recombinant Avian Paramyxovirus Serotypes 2 Vector-Based Vaccine Induces Protection against H9N2 Avian Influenza in Chicken.
10/2021	Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiufan Liu Research Topics

Disease

71	Influenza in Birds (Avian Flu) 12/2022 - 06/2002
48	Infections 08/2022 - 04/2002
10	Virus Diseases (Viral Diseases) 12/2021 - 03/2009
9	Human Influenza (Influenza) 01/2022 - 11/2010
3	Rheumatoid Arthritis 12/2020 - 01/2020
3	Viremia 01/2020 - 07/2015
2	Newcastle Disease 01/2022 - 03/2011
2	Neoplasms (Cancer) 01/2021 - 07/2014
2	Inflammation (Inflammations) 07/2020 - 11/2017
2	Body Weight (Weight, Body) 02/2020 - 01/2020
2	Necrosis 10/2018 - 09/2012
2	Lung Injury 04/2017 - 08/2016
1	Coronavirus Infections 12/2020
1	Dehydration (Water Stress) 06/2020

Drug/Important Bio-Agent (IBA)

39	VaccinesIBA 12/2022 - 02/2009
24	Hemagglutinins (Hemagglutinin)IBA 01/2022 - 06/2002
22	Proteins (Proteins, Gene)FDA Link 06/2022 - 04/2002
16	Biological ProductsIBA 03/2022 - 12/2009
12	Neuraminidase (Sialidase)IBA 01/2022 - 10/2008
8	EpitopesIBA 08/2022 - 03/2013
8	AntibodiesIBA 08/2022 - 03/2018
7	Amino Acids FDA Link 01/2022 - 06/2002
6	Antiviral Agents (Antivirals)IBA 12/2021 - 08/2013
5	Inactivated VaccinesIBA 01/2022 - 04/2010
4	Complement System Proteins (Complement)IBA 04/2017 - 06/2013
3	Peptides (Polypeptides)IBA 12/2022 - 10/2021
3	Small Interfering RNA (siRNA)IBA 01/2022 - 11/2008
3	NucleotidesIBA 01/2022 - 08/2003
3	RNA (Ribonucleic Acid)IBA 12/2021 - 01/2019
3	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2019
3	Pharmaceutical PreparationsIBA 12/2020 - 01/2013
3	IronIBA 04/2020 - 07/2012
2	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 01/2018
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 04/2017
2	Viral ProteinsIBA 03/2021 - 08/2014
2	CollagenIBA 01/2021 - 01/2018
2	Leflunomide (Arava)FDA LinkGeneric 12/2020 - 01/2020
2	teriflunomideIBA 12/2020 - 01/2020
2	Neutralizing AntibodiesIBA 11/2020 - 01/2019
2	Janus Kinase InhibitorsIBA 10/2020 - 01/2020
2	Janus KinasesIBA 10/2020 - 01/2020
2	Immunoglobulin A (IgA)IBA 09/2020 - 04/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 11/2016
2	Synthetic Vaccines (Recombinant Vaccines)IBA 12/2018 - 05/2012
2	Attenuated VaccinesIBA 01/2018 - 01/2017
2	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2017 - 01/2016
2	sialic acid receptorIBA 01/2017 - 01/2016
2	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2017 - 01/2012
2	EmulsionsIBA 01/2016 - 01/2012
2	CytokinesIBA 02/2014 - 08/2013
2	Virulence Factors (Pathogenicity Factors)IBA 10/2013 - 07/2008
1	AntigensIBA 08/2022
1	Combined VaccinesIBA 05/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	mesoxalonitrileIBA 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	AMP-Activated Protein KinasesIBA 01/2022
1	Sirtuin 3IBA 01/2022
1	Tricarboxylic AcidsIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	NAD (NADH)IBA 01/2022
1	Adenosine Monophosphate (AMP)IBA 01/2022
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2022
1	Adenosine Triphosphate (ATP)IBA 01/2022
1	triphosphoric acid (triphosphate)IBA 01/2022
1	OccludinIBA 01/2022
1	6- deoxy- N- (7- nitrobenz- 2- oxa- 1,3- diazol- 4- yl)aminoglucose (NBDG)IBA 01/2022
1	Deoxyglucose (2 Deoxy D glucose)IBA 01/2022
1	Carbonyl Cyanide m-Chlorophenyl Hydrazone (CCCP)IBA 01/2022
1	RNA Precursors (Precursor, mRNA)IBA 12/2021
1	Long Noncoding RNAIBA 12/2021
1	Marker VaccinesIBA 10/2021
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 03/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021
1	Methionine (L-Methionine)FDA Link 11/2020
1	Immunomodulating AgentsIBA 10/2020
1	ferric oxide (iron oxide)IBA 09/2020
1	ChitosanIBA 09/2020
1	Inositol (Myoinositol)IBA 07/2020
1	EnzymesIBA 07/2020
1	PotassiumIBA 06/2020
1	LithiumIBA 06/2020
1	Ion Channels (Ion Channel)IBA 06/2020
1	potassium niobateIBA 06/2020
1	SiderophoresIBA 04/2020
1	EnterobactinIBA 04/2020
1	SuspensionsIBA 03/2019
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2019
1	LipidsIBA 01/2019
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 10/2018
1	NucleolinIBA 10/2018
1	Messenger RNA (mRNA)IBA 10/2018
1	Complementary RNA (cRNA)IBA 10/2018
1	Annexin A2 (Annexin II)IBA 09/2018
1	PlasminogenIBA 09/2018
1	Fibrinolysin FDA Link 09/2018
1	NF-kappa B (NF-kB)IBA 11/2017

Therapy/Procedure

2	Intranasal Administration 01/2012 - 11/2010
1	Therapeutics 12/2021